Innovative collaborations propel Poolbeg Pharma’s drug development efforts

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Jeremy Skillington, the CEO of Poolbeg Pharma, will be presenting at the Cell & Gene Therapy International Europe 2024 event. His presentation will focus on a novel approach using p38 MAPK inhibition to prevent Cytokine Release

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Liam Tremble, Principal Scientist at Poolbeg Pharma, is deeply involved in developing innovative treatments for diseases with significant unmet medical needs. His current work spans oncology, infectious diseases, and endocrinology, where he leads drug discovery efforts.

The medtech industry is at a crucial point, experiencing significant growth driven by the Covid-19 pandemic, which spurred a wave of innovation and investment. Though the sector has now returned to pre-pandemic growth trends, this transition

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where